5Folkman J. Role of angiogenesis in tumor growth and metastasis [J]. Semin Oncol, 2002, 29(16): 15-18. 被引量：1
6Shichiri M, Hirata Y. Antiangiogenesis signals by endostatin [J]. FASEB J, 2001, 15(6):1044-1053. 被引量：1
7Huang X, Wong MK, Zhao Q, et al. Soluble recombinant endostatin purified from Escherichia coli: antiangiogenic activity and antitumor effect [J]. Cancer Res, 2001,61 (2):478-481. 被引量：1
8Hansma AH. A phase I safety and pharmacokinetic(PK) study of continuous intravenous rh-endostatin followed by subcutaneous (s.c.) administration in patients with advanced cancer. Proc ASCO, 2002. 被引量：1
9Eder J P Jr, Supko JG, Clark JW, et al. Phase Ⅰ clinical trial of recombinant human endostatin administered as a short intravenous infusion repeated daily [J]. J Clin Oncol, 2002, 20(18):3772-3784. 被引量：1
10Herbst RS, Hess KR, Tran HT, et al. Phase Ⅰ study of recombinant human endostatin in patients with advanced solid tumors [J]. J Clin Oncol, 2002, 20(18):3792-3803. 被引量：1
3Bradshaw M, Mansfield A, Peikert T. The role of vascularendothelial growth factor in the pathogenesis, diagnosis andtreatment of malignant pleural effusion [J]. Curr Oncol Rep,2013,15(3):207-216. 被引量：1
4Cheng D,Kong H, Li Y. Prognostic values of VEGF and IL-Sin malignant pleural effusion in patients with lung cancer[J].Biomarkers’2013,18(5) :386-390. 被引量：1
7Ma X, Yao Y, Yuan D, et al. Recombinant human endostatinendostar suppresses angiogenesis and lymphangiogenesis ofmalignant pleural effusion in mice[J], PLoS One.2012,7(12):e53449. 被引量：1
